Biotech entity
Every one of those 2 sits in a single category, pharma. BeiGene is most often covered alongside China, which appears in 2 of these 2 stories. Across a 13-day span, the pace is roughly 1.1 stories per week. The 8 average consequence score is above the beat benchmark of 6.1 in the same window.
Last mentioned: Mar 19, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, pharma. BeiGene is most often covered alongside China, which appears in 2 of these 2 stories. Across a 13-day span, the pace is roughly 1.1 stories per week. The 8 average consequence score is above the beat benchmark of 6.1 in the same window. Each story carries 2 original sources on average, compared with 3.6 for the broader beat in this window. We currently track 2 Biotech stories that mention BeiGene, published between March 7, 2026 and March 19, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 188 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering BeiGene. Shared-story counts are live from our verified record — not editorial picks.
Healthy China 2030 Deadline
Target date for achieving major healthcare and biotech self-sufficiency milestones.
Official Launch
President Xi Jinping unveils the 15th FYP at the National People's Congress.
15th FYP Announcement
China officially prioritizes tech self-reliance as the central pillar of the 2026-2030 plan.
Implementation Phase
Expected rollout of specific subsidies and domestic-first procurement policies.
15th FYP Drafting
Central Committee reviews the initial draft of the 2026-2030 strategic plan.
Geopolitical Escalation
U.S. introduces Biosecure Act, targeting major Chinese biotech entities.
14th Five-Year Plan
Initial focus on 'Dual Circulation' and building basic biotech infrastructure.
14th FYP Implementation
Focus on 'Dual Circulation' and initial biotech innovation pivot.
President Xi Jinping’s 15th Five-Year Plan (2026-2030) positions biotechnology as a cornerstone of "New Quality Productive Forces," prioritizing domestic innovation and supply chain self-sufficiency. This strategic shift aims to decouple China’s life sciences sector from Western dependencies while accelerating the commercialization of cell and gene therapies.
China has officially signaled a shift toward total technological self-reliance in its 15th Five-Year Plan, prioritizing the domestic life sciences and pharmaceutical sectors. This strategic pivot aims to insulate China’s healthcare infrastructure from global supply chain volatility and geopolitical pressures while fostering a homegrown innovation ecosystem.
BeiGene is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
